Open AccessAcute, short‐ and long‐term efficacy of oral bevantolol in patients with coronary artery disease: A placebo‐controlled, randomized, double‐blind study
Author(s) -
Gimeno J. V.,
Ferrer J.,
Olague J.,
Bordes P.,
Serra J.,
Estruch G.,
Mainer V.,
Algarra F. J.
Publication year - 1986
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960090913
Subject(s) - medicine , placebo , propranolol , cardiology , coronary artery disease , angina , anesthesia , myocardial infarction , alternative medicine , pathology
The efficacy and safety of bevantolol (new cardioselective beta‐blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris. Acute effects on heart rate (HR) and pulmonary function (forced expiratory volume in the first second, FEV 1 , and vital capacity, VC) (doubleblind placebo, propranolol, 80 mg, and bevantolol, 150 mg) and the antianginal efficacy during early (doubleblind placebo period) and chronic bevantolol therapy (long‐term follow‐up for 52 weeks) were studied. Bevantolol reduces HR in the same way as propranolol (both p<0.01). Pulmonary function is modified significantly only by propranolol (decreasing FEV 1 , p<0.05). Bevantolol reduces antianginal attacks and nitroglycerin consumption (p<0.01) and improves exercise tolerance (p<0.01) during early and chronic therapy.